4D Molecular Therapeutics Investor Relations Material
Latest events
Study Result
4D Molecular Therapeutics
Q1 2025
8 May, 2025
Q4 2024
28 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from 4D Molecular Therapeutics Inc
Access all reports
4D Molecular Therapeutics Inc. (FDMT) is a clinical-stage biotherapeutics company engaged in the development of genetic medicines using a proprietary therapeutic vector evolution platform. The company is focused on addressing serious unmet medical needs across three main therapeutic areas: ophthalmology, cardiology, and pulmonology. Its portfolio includes genetic medicine product candidates in various stages of clinical trials. FDMT is headquartered in Emeryville, California, and its shares are listed on the NASDAQ.
Key slides for 4D Molecular Therapeutics Inc
Study Result
4D Molecular Therapeutics Inc
Study Result
4D Molecular Therapeutics Inc
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
FDMT
Country
🇺🇸 United States